These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 24528069)

  • 21. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment.
    D'Alessandro G; Grimaldi A; Chece G; Porzia A; Esposito V; Santoro A; Salvati M; Mainiero F; Ragozzino D; Di Angelantonio S; Wulff H; Catalano M; Limatola C
    Oncotarget; 2016 May; 7(21):30781-96. PubMed ID: 27096953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
    Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
    Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. KLF8 Promotes Temozolomide Resistance in Glioma Cells via β-Catenin Activation.
    Yu G; Wu F; Wang E
    Cell Physiol Biochem; 2016; 38(4):1596-604. PubMed ID: 27081861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
    Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Integrin αVβ3 silencing sensitizes malignant glioma cells to temozolomide by suppression of homologous recombination repair.
    Christmann M; Diesler K; Majhen D; Steigerwald C; Berte N; Freund H; Stojanović N; Kaina B; Osmak M; Ambriović-Ristov A; Tomicic MT
    Oncotarget; 2017 Apr; 8(17):27754-27771. PubMed ID: 27487141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of ILK promotes temozolomide resistance in glioma cells.
    Liang F; Wang B; Bao L; Zhao YS; Zhang SM; Zhang SQ
    Mol Med Rep; 2017 Mar; 15(3):1297-1304. PubMed ID: 28138714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Silence of bFGF enhances chemosensitivity of glioma cells to temozolomide through the MAPK signal pathway.
    Wang Q; Du J; Xu B; Xu L; Wang X; Liu J; Wang J
    Acta Biochim Biophys Sin (Shanghai); 2016 Jun; 48(6):501-8. PubMed ID: 27189511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.
    Wang G; Sai K; Gong F; Yang Q; Chen F; Lin J
    Mol Med Rep; 2014 May; 9(5):1799-805. PubMed ID: 24626950
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CEBPB upregulates P4HA2 to promote the malignant biological behavior in IDH1 wildtype glioma.
    Wang S; Wu J; Zhao W; Li M; Li S
    FASEB J; 2023 Apr; 37(4):e22848. PubMed ID: 36906285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. IDH1 gene mutation activates Smad signaling molecules to regulate the expression levels of cell cycle and biological rhythm genes in human glioma U87‑MG cells.
    Gao Y; Wu Y; Zhang N; Yuan H; Wang F; Xu H; Yu J; Ma J; Hou S; Cao X
    Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MEK2 is a prognostic marker and potential chemo-sensitizing target for glioma patients undergoing temozolomide treatment.
    He H; Yao M; Zhang W; Tao B; Liu F; Li S; Dong Y; Zhang C; Meng Y; Li Y; Hu G; Luo C; Zong H; Lu Y
    Cell Mol Immunol; 2016 Sep; 13(5):658-68. PubMed ID: 26189368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoallelic IDH1 R132H Mutation Mediates Glioma Cell Response to Anticancer Therapies via Induction of Senescence.
    Zhan D; Ma D; Wei S; Lal B; Fu Y; Eberhart C; Laterra J; Ying M; Li Y; Meeker A; Lopez-Bertoni H; Xia S
    Mol Cancer Res; 2021 Nov; 19(11):1878-1888. PubMed ID: 34348994
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of IFN-beta on human glioma cell lines with temozolomide resistance.
    Yoshino A; Ogino A; Yachi K; Ohta T; Fukushima T; Watanabe T; Katayama Y; Okamoto Y; Naruse N; Sano E
    Int J Oncol; 2009 Jul; 35(1):139-48. PubMed ID: 19513561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IDH1 mutation diminishes aggressive phenotype in glioma stem cells.
    Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J
    Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced.
    Zhu H; Zhang Y; Chen J; Qiu J; Huang K; Wu M; Xia C
    PLoS One; 2017; 12(1):e0169038. PubMed ID: 28052098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temozolomide inhibits cellular growth and motility via targeting ERK signaling in glioma C6 cells.
    Wang Y; Gao S; Wang W; Liang J
    Mol Med Rep; 2016 Dec; 14(6):5732-5738. PubMed ID: 27878252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multifaceted resistance of gliomas to temozolomide.
    Bocangel DB; Finkelstein S; Schold SC; Bhakat KK; Mitra S; Kokkinakis DM
    Clin Cancer Res; 2002 Aug; 8(8):2725-34. PubMed ID: 12171906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity.
    Remington M; Chtchetinin J; Ancheta K; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2009 Feb; 11(1):22-32. PubMed ID: 18812520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.